INTRODUCING
LACTOVID
An investigational new drug for the prevention and treatment of COVID-19, including long COVID.
LACTOVID is structural advantaged to provide potent protection against variants, using ingredients with a long history of safety, and is rapidly deployable.
THE PROBLEM
A continuing disease with huge unmet needs for treatment
and prevention in terms of availability and safety
Global governments’ massive investments into healthcare systems and new product innovation to combat the emergence of COVID have had unprecedented success in the speed of vaccines and treatment products. Yet even as we transition to a new normal, many problems still exist.
• Variants: emerging globally to become dominant forms with waves happening every 6 months
• Waning Effectiveness: efficacy of existing COVID strategies is fading as vaccines and treatments targeting a specific variant are more susceptible to virus mutations
• Long COVID: the CDC estimates nearly 20M adults currently suffer from long COVID, with many facing limitations in day-to-day activities
• Storage and stability: mRNA vaccines are not stable under normal conditions
• Safety: mRNA vaccines and the active ingredients in oral treatments (such as Paxlovid) are new drugs without a long history of safety
• Drug interactions: Current oral treatments have multiple dangerous drug interactions including common supplements, birth control, cholesterol medications, and Viagra among others. Side effects include distortion of sense of taste, liver function, jaundice, abdominal pain, high blood pressure, muscle aches, and more.
THE SOLUTION
A low risk, oral drug combination capable
of inhibiting COVID at a large scale
A huge opportunity gap exists in the market for an oral drug for the prevention and treatment of COVID, including long COVID.
• Research results: our two underlying ingredients show direct antiviral activity against SARS-CoV-2 with synergistic results inhibiting replication, shedding, and cell killing: 99% inhibition of COVID using E6 lung cells. Results holding up in in vivo mice studies. Studies in humans with the individual ingredients show effect on COVID.
• Robust to variants: underlying mechanisms of action prevent formation at the coronavirus replication site suggesting efficacy against all coronaviruses and variants
• Market: different doses for the prevention as well as treatment of COVID. Prevention includes taking it when traveling, a family member tests positive, during surges – not only after a positive COVID test. Filing an IND to investigate its clinical impact in relieving long COVID
• Combination: using a combination of two ingredients with different mechanisms of action make it much more difficult for a virus to develop resistance (e.g. HIV and Hep C combination treatments)
• Safety: active ingredients studied for decades with a long history of safety and FDA approval. Very low side-effects and dangerous drug interactions.
COVID-19 AND LACTOVID
Lactovid fulfills the need for an effective drug combination capable of inhibiting COVID across variants at a large scale
To manage COVID and mutations, we need novel solutions. We believe that an oral, direct-acting antiviral drug whose active ingredients have a long history of safety can help fulfill the need for both prevention and treatment worldwide. The value and health impact of an antiviral compound that curbs infection and reduces symptoms would be highly useful to: (1) control local outbreaks or for home-based management, (2) protect immunocompromised patients for who vaccination and other strategies are not suitable, and (3) slow the spread of variants of concern that could escape vaccine neutralization.
While vaccines and new prescription drugs play an important role within the existing COVID response, we urgently need an effective product for the prevention and treatment of COVID-19 (including variants and long COVID) to inhibit progression of the disease, reduce the burden on national healthcare systems, and save lives on a global scale.
Lactovid is an investigational new oral drug, with demonstrated direct antiviral activity against COVID-19, including long COVID.
Antiviral activity of Lactovid against COVID-19 has been demonstrated in in vitro and in vivo studies. We are working in concert with regulatory authorities and undertaking a clinical study to establish that LACTOVID can be a safe and effective drug in the fight against COVID-19. LACTOVID is not yet licensed or approved for any indication in the U.S. or any other country.
Advantages.
Lactovid has many advantages.
Safety.
New drugs and techniques have unknown risks. Our two underlying active ingredients each have a long history of safety in human use. The safety profile of its two well-known ingredients have fewer side-effects and dangerous drug interactions compared to newer drugs.
Combination.
The two active ingredients of Lactovid exhibit multiple and different mechanisms of action against COVID-19. This creates a synergistic efficacy against SARS-CoV-2 and makes it much more difficult for viruses to develop resistance (e.g. waning vaccine efficiency and COVID rebound).
These mechanisms inhibit formation at the coronavirus replication site suggesting efficacy against all SARS-CoV-2 variants of concern.
Availability.
Current and proposed oral treatments are available only by prescription, limited to certain treatment criteria (e.g. positive COVID test), and not possible for people with drug interactions (including common supplements, birth control, cholesterol, heart medication, Viagra, among others).
Lactovid aims to be available for both the prevention and treatment of COVID, including long COVID. Prevention includes periods such as when traveling, a family member tests positive, and during local surges.
Where we are now.
We are engaged with the global regulatory authorities with the goal of completing and progressing high quality submissions and rigorous scientific results through the structured regulatory process.
We anticipate successful upcoming clinical trials results under an IND. Our in vitro research was confirmed in vivo with ACE2 transgenic mice, allowing us to estimate dosage levels in humans. Recent research also shows a positive benefit for COVID in patients using each of Lactovid’s individual ingredients. Based on known mechanisms of action, we expect Lactovid to inhibit all coronaviruses, including all SARS-CoV-2 variants of concern.
Our goal is to accelerate the clinical impact and commercialization of our small molecule platforms through partnerships that allow us to drive the rapid advancement of our pipeline.
For investment opportunities or to learn more, contact us below.
Frequently Asked Questions
What is Lactovid?
Lactovid is an investigational new drug for preventing and treatment of COVID.
Why use Lactovid for COVID?
Lactovid is a combination of two ingredients with long histories of safety.
Each component of Lactovid has been shown to exert direct antiviral activity against the virus that causes COVID.
The combination of two antiviral agents has important advantages compared to Paxlovid and other existing COVID treatments.
What about new variants of concern?
The action of Lactovid is to prevent the formation of the coronavirus replication site.
Since all coronaviruses use this site for replication, data suggests that Lactovid will be effective against new SARS-CoV-2 variants and all coronaviruses.